1. Nevin RL. Mefloquine and posttraumatic stress disorder. In: Ritchie EC, ed. Textbook of military medicine. Forensic and ethical issues in military behavioral health. Washington, DC: Borden Institute; 2015:277–96.
2. Magill A, Cersovsky S, DeFraites R. Special considerations for US military deployments. CDC Yellow Book—Travelers’ Health Chapter 8.
http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-8-advising-travelers-with-specific-needs/special-considerations-for-us-military-deployments
(2014). Accessed 8 May 2015.
3. Walter Reed Army Institute of Research. Neurotoxicity associated with mefloquine, an anti-malarial drug: small business technology transfer (STTR) solicitation topic number A06-T034 (Army).
http://www.dodsbir.net/sitis/archives_display_topic.asp?Bookmark=28959
. (2006). Accessed 8 May 2015.
4. Nevin RL. Idiosyncratic quinoline central nervous system toxicity: historical insights into the chronic neurological sequelae of mefloquine. Int J Parasitol Drugs Drug Resist. 2014;4(2):118–25.
5. U.S. Food and Drug Administration. Release P03–52. FDA creates medication guide for Lariam. 2003.